DK3619324T3 - Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf - Google Patents

Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf

Info

Publication number
DK3619324T3
DK3619324T3 DK18794391.5T DK18794391T DK3619324T3 DK 3619324 T3 DK3619324 T3 DK 3619324T3 DK 18794391 T DK18794391 T DK 18794391T DK 3619324 T3 DK3619324 T3 DK 3619324T3
Authority
DK
Denmark
Prior art keywords
growth factors
fibroblast growth
therapeutic applications
recombinant modified
modified fibroblast
Prior art date
Application number
DK18794391.5T
Other languages
English (en)
Inventor
David Eveleth
Jennifer Jenkins-Eveleth
Amuthakannan Subramaniam
Ralph Bradshaw
Original Assignee
Trefoil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trefoil Therapeutics Inc filed Critical Trefoil Therapeutics Inc
Application granted granted Critical
Publication of DK3619324T3 publication Critical patent/DK3619324T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK18794391.5T 2017-05-05 2018-05-04 Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf DK3619324T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762502529P 2017-05-05 2017-05-05
US201762502540P 2017-05-05 2017-05-05
US201762584624P 2017-11-10 2017-11-10
PCT/US2018/031189 WO2018204847A2 (en) 2017-05-05 2018-05-04 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DK3619324T3 true DK3619324T3 (da) 2025-09-22

Family

ID=64016756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18794391.5T DK3619324T3 (da) 2017-05-05 2018-05-04 Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf

Country Status (12)

Country Link
US (2) US11479591B2 (da)
EP (2) EP3619324B1 (da)
JP (2) JP2020518287A (da)
KR (1) KR20200078425A (da)
CN (1) CN111148755A (da)
AU (1) AU2018261021B2 (da)
BR (1) BR112019023260A2 (da)
CA (1) CA3062473A1 (da)
DK (1) DK3619324T3 (da)
ES (1) ES3041527T3 (da)
MX (1) MX2019013210A (da)
WO (1) WO2018204847A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3619324T3 (da) 2017-05-05 2025-09-22 Trefoil Therapeutics Inc Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療
WO2021261946A1 (ko) 2020-06-26 2021-12-30 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
IL308496A (en) * 2021-05-14 2024-01-01 Claris Biotherapeutics Inc Growth factor compounds for the treatment of eye diseases
CN113289005B (zh) * 2021-07-06 2022-05-31 温州医科大学 rhFGF-21在制备治疗干眼症药物中的应用
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
US12357843B2 (en) 2022-03-25 2025-07-15 Cutera, Inc. Methods of skin treatment with laser light
CN115177717B (zh) * 2022-08-31 2026-02-06 贵州医科大学附属医院 一种治疗眼表及角膜上皮疾病的药物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022758A (en) 1973-06-19 1977-05-10 Ab Kabi Isolation of coagulation factors I and VIII from biological material
US5552528A (en) * 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
US5223483A (en) 1987-10-22 1993-06-29 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US5312911A (en) 1987-10-22 1994-05-17 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5510329A (en) 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
GB2223496B (en) * 1988-08-08 1992-05-27 British Bio Technology Synthetic gene encoding mature human acid fibroblast growth factor
US6780837B1 (en) 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US20040071787A1 (en) 1996-05-01 2004-04-15 Maine Medical Center Research Institute Pharmacologic, therapeutic and diagnostic regulation of FGF-1 export
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
AU3170499A (en) 1998-04-28 1999-11-16 Eisai Co. Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2001072957A2 (en) 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
AU8825601A (en) * 2000-08-15 2002-02-25 Phage Biotechnology Corp A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
US20100254900A1 (en) 2002-03-18 2010-10-07 Campbell Phil G Biocompatible polymers and Methods of use
WO2005048942A2 (en) 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
AU2004303783A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
US7767656B2 (en) 2005-04-25 2010-08-03 Molly S Shoichet Blends of temperature sensitive and anionic polymers for drug delivery
CN100334114C (zh) 2005-07-22 2007-08-29 彭隽 一种新型融合蛋白及其制备
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
SG162834A1 (en) 2006-07-14 2010-07-29 Genentech Inc Refolding of recombinant proteins
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US7595296B1 (en) 2006-11-09 2009-09-29 Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
NZ621196A (en) * 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
WO2012124639A1 (ja) 2011-03-11 2012-09-20 株式会社カネカ 改変型アミノ基転移酵素、その遺伝子、およびそれらを利用した光学活性アミノ化合物の製造方法
WO2013036708A2 (en) 2011-09-07 2013-03-14 The Regents Of The University Of California Compositions and methods for tissue repair with extracellular matrices
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
WO2014024173A2 (en) 2012-08-10 2014-02-13 Florida State University Research Foundation Recombinant human fibroblast growth factor-1 as a novel therapeutic for ischemic diseases and methods thereof
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
US20150253308A1 (en) * 2013-05-03 2015-09-10 Orasis Compositions and methods of treating glaucoma
HRP20200257T1 (hr) * 2013-09-25 2020-09-04 Trefoil Therapeutics, Llc Izmjenjeni faktori rasta fibroblasta-1 za liječenje okularnih poremećaja
TWI634898B (zh) * 2013-10-07 2018-09-11 雅祥生技醫藥股份有限公司 經修飾之人類酸性纖維母細胞生長因子及其組合物
US20150104494A1 (en) * 2013-10-11 2015-04-16 Ohio State Innovation Foundation Methods for repair of ear canal tissue defects
WO2015061351A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
WO2015198175A1 (en) * 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Design of fgf-1 mutants to effectively eliminate reactive cysteine residues
WO2016172156A2 (en) * 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
CA2983153A1 (en) 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
EP3336178B1 (en) * 2015-08-13 2020-03-18 Fujifilm Corporation Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells
WO2017075260A1 (en) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
EP3436608A4 (en) 2016-03-28 2019-12-04 Trefoil Therapeutics, Inc. MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF
DK3619324T3 (da) 2017-05-05 2025-09-22 Trefoil Therapeutics Inc Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf
SG11201912799SA (en) 2017-06-23 2020-01-30 Zhuhai Essex Bio Pharmaceutical Co Ltd Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
JP2023532046A (ja) 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療
WO2023019218A1 (en) 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
TW202327641A (zh) 2021-09-14 2023-07-16 美商三葉草治療有限公司 使用經修飾之fgf-1多肽之治療方法

Also Published As

Publication number Publication date
EP3619324B1 (en) 2025-07-09
EP3619324A2 (en) 2020-03-11
US20230130851A1 (en) 2023-04-27
JP2024112824A (ja) 2024-08-21
BR112019023260A2 (pt) 2022-02-22
AU2018261021A1 (en) 2019-12-12
CA3062473A1 (en) 2018-11-08
US11479591B2 (en) 2022-10-25
US12600756B2 (en) 2026-04-14
WO2018204847A2 (en) 2018-11-08
RU2019139358A (ru) 2021-06-07
CN111148755A (zh) 2020-05-12
EP3619324A4 (en) 2020-12-30
ES3041527T3 (en) 2025-11-12
KR20200078425A (ko) 2020-07-01
US20200190158A1 (en) 2020-06-18
JP2020518287A (ja) 2020-06-25
RU2019139358A3 (da) 2021-08-26
AU2018261021B2 (en) 2024-09-12
EP4621067A3 (en) 2025-11-19
EP4621067A2 (en) 2025-09-24
MX2019013210A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
IL268593A (en) Polypeptide variants and uses thereof
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
DK3494134T3 (da) Manipulerede polypeptider og deres anvendelse
PL3661954T3 (pl) Muteiny interleukiny 21 i sposoby leczenia
EP3619324A4 (en) RECOMBINATED MODIFIED FIBROBLASTIC GROWTH FACTORS AND THEIR THERAPEUTIC USES
EP3576765A4 (en) TARGETED ENGINEERING INTERFERON AND USES OF IT
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3988117T3 (da) Terapeutiske antistoffer og deres anvendelser
DK3322430T3 (da) Antiinflammatoriske peptider, og anvendelser deraf
EP3600156C0 (de) Herzklappen-implantat und herzklappen-implantat-system
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3678687T3 (da) Mutant fgf-21 peptidkonjugater og anvendelser deraf
DK3618848T3 (da) Biologisk aktive komplekser og terapeutiske anvendelser deraf
DK3481859T3 (da) Opløselig fibroblastvækstfaktorreceptor 3 (SFGFR3)-polypeptider og anvendelser deraf
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
DK3720875T3 (da) Antimikrobielle peptider og fremgangsmåder til anvendelse deraf
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
EP3723771A4 (en) Recombinant adenoviruses and uses thereof
EP3570867A4 (en) THERAPEUTIC PEPTIDES AND NEUROPROTECTORS
DK3590523T3 (da) Vækstfremmende peptider og anvendelser deraf
DK3737399T3 (da) Atf5-peptidvarianter og anvendelser deraf